| Literature DB >> 30081839 |
Ulrich Marcus1, Christiana Nöstlinger2, Magdalena Rosińska3, Nigel Sherriff4, Lorenzo Gios5, Sonia F Dias6, Ana F Gama7, Igor Toskin8, Ivailo Alexiev9, Emilia Naseva10, Susanne Barbara Schink11, Massimo Mirandola5.
Abstract
BACKGROUND: Reducing the number of people with undiagnosed HIV infection is a major goal of HIV control and prevention efforts in Europe and elsewhere. We analysed data from a large multi-city European bio-behavioural survey conducted among Men who have Sex with Men (MSM) for previously undiagnosed HIV infections, and aimed to characterise undiagnosed MSM who test less frequently than recommended.Entities:
Keywords: Biobehavioural survey; Europe; HIV; Men having sex with men; Undiagnosed HIV infection
Mesh:
Year: 2018 PMID: 30081839 PMCID: PMC6080551 DOI: 10.1186/s12879-018-3249-8
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Sialon II study participants by study site, testing history and measured HIV status after exclusion of participants already known to have HIV and with indeterminate HIV status knowledge
| city | HIV negative (n) | percentage tested for HIV in the last 12 months (%) | undiagnosed HIV infection (n) | percentage with undiagnosed HIV (%) | undiagnosed HIV, negative HIV pre-test within recent 12 months (n) | undiagnosed HIV infection, no pre-test or test longer ago than 12 months (n) | percentage of undiagnosed HIV that may not be recent (%) | Total (N) |
|---|---|---|---|---|---|---|---|---|
| Barcelona | 334 | 66.2% | 21 | 5.9% | 16 | 5 | 23.8% | 355 |
| Bratislava | 376 | 35.5% | 15 | 3.8% | 6 | 9 | 60.0% | 391 |
| Brighton | 331 | 56.7% | 15 | 4.3% | 10 | 5 | 33.3% | 346 |
| Brussels | 327 | 63.5% | 7 | 2.1% | 5 | 2 | 28.6% | 334 |
| Bucharest | 146 | 42.9% | 15 | 9.3% | 7 | 8 | 53.3% | 161 |
| Hamburg | 336 | 52.1% | 15 | 4.3% | 11 | 4 | 26.7% | 351 |
| Lisbon | 300 | 63.8% | 29 | 8.8% | 23 | 6 | 20.7% | 329 |
| Ljubljana | 329 | 50.9% | 7 | 2.1% | 5 | 2 | 28.6% | 336 |
| Sofiaa | 344 | 12 | 3.4% | 356 | ||||
| Stockholm | 334 | 49.9% | 3 | 0.9% | 2 | 1 | 33.3% | 337 |
| Verona | 367 | 41.9% | 10 | 2.7% | 2 | 8 | 80.0% | 377 |
| Vilnius | 314 | 38.9% | 5 | 1.6% | 2 | 3 | 60.0% | 319 |
| Warsaw | 346 | 57.9% | 22 | 6.0% | 17 | 5 | 22.7% | 368 |
| Total | 4184 | 176 | 4.0% | 4360 | ||||
| Total w/o Sofia | 3840 | 51.9% | 164 | 106 | 58 | 33.0% | 4004 |
adata on recency of last HIV testing are missing for Sofia due to incorrect translation of the question in the Bulgarian questionnaire version
Fig. 1Age distribution and prevalence of HIV infection and undiagnosed HIV by age group in the Sialon II participants, Sialon II biobehavioural survey, 2013–2014
Distribution of Sialon II study participants who were not aware of having HIV by laboratory-determined HIV status and year of last HIV test - overall and by test recency group
| uHIV - study sample | uHIVunk - last HIV test not within 12 months of recruitment into the study | ||||
|---|---|---|---|---|---|
| Year of last reported test | HIV negative | HIV positive, undiagnosed | Year of last reported test | HIV negative | HIV positive, undiagnosed |
| 1987 | 1 | 0 | 1987 | 1 | 0 |
| 1988 | 1 | 0 | 1988 | 1 | 0 |
| 1989 | 2 | 0 | 1989 | 2 | 0 |
| 1990 | 5 | 0 | 1990 | 5 | 0 |
| 1991 | 1 | 0 | 1991 | 1 | 0 |
| 1992 | 3 | 0 | 1992 | 3 | 0 |
| 1993 | 2 | 0 | 1993 | 2 | 0 |
| 1994 | 1 | 0 | 1994 | 1 | 0 |
| 1995 | 4 | 1 | 1995 | 4 | 1 |
| 1996 | 2 | 1 | 1996 | 2 | 1 |
| 1997 | 5 | 1 | 1997 | 5 | 1 |
| 1998 | 7 | 0 | 1998 | 7 | 0 |
| 1999 | 6 | 0 | 1999 | 6 | 0 |
| 2000 | 18 | 0 | 2000 | 18 | 0 |
| 2001 | 10 | 0 | 2001 | 10 | 0 |
| 2002 | 13 | 1 | 2002 | 13 | 1 |
| 2003 | 15 | 0 | 2003 | 15 | 0 |
| 2004 | 14 | 0 | 2004 | 14 | 0 |
| 2005 | 39 | 2 | 2005 | 39 | 2 |
| 2006 | 22 | 2 | 2006 | 22 | 2 |
| 2007 | 39 | 0 | 2007 | 39 | 0 |
| 2008 | 61 | 0 | 2008 | 61 | 0 |
| 2009 | 80 | 4 | 2009 | 80 | 4 |
| 2010 | 151 | 13 | 2010 | 151 | 13 |
| 2011 | 267 | 8 | 2011 | 267 | 8 |
| 2012 | 785 | 47 | 2012 | 205 | 10 |
| 2013 | 1306 | 70 | 2013 | 30 | 2 |
| 2014 | 32 | 0 | never tested/year missing | 864 | 13 |
| year missinga | 1292 | 26 | Total | 1868 | 58 |
| Total | 4184 | 176 | |||
| uHIVinc - last test within 12 months before recruitment into the study | |||||
| 2012 | 580 | 37 | |||
| 2013 | 1276 | 68 | |||
| 2014 | 32 | 0 | |||
| year missing, test within the last 12 months reported | 84 | 1 | |||
| Total | 1972 | 106 | |||
aincludes 356 participants from Sofia whose last HIV test date could not be determined
Associations between demographic and behaviour variables and undiagnosed HIV infection in participants of the European Sialon II biobehavioural survey
| uHIVinc | uHIVunk | uHIV | N | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Odds Ratio | [95% Conf. Interval] | Odds Ratio | [95% Conf. Interval] | Odds Ratio | [95% Conf. Interval] | |||||||||
| Age group | 18–24 | ref. | 923 | |||||||||||
| 25–34 |
|
| 1.58 | 7.07 | 1.69 | 0.25 | 0.70 | 4.07 |
|
| 1.56 | 4.50 | 1730 | |
| 35–44 |
|
| 1.37 | 6.80 |
|
| 1.18 | 6.73 |
|
| 1.66 | 5.06 | 970 | |
| 45–54 | 2.37 | 0.07 | 0.94 | 5.97 | 2.00 | 0.19 | 0.72 | 5.59 |
|
| 1.11 | 4.19 | 488 | |
| 55+ | 1.36 | 0.66 | 0.35 | 5.20 | 1.39 | 0.64 | 0.35 | 5.46 | 1.34 | 0.54 | 0.52 | 3.44 | 244 | |
| Migration status | native | ref. | 3565 | |||||||||||
| emigrant | 2.14 | 0.20 | 0.63 | 7.20 |
|
| 1.45 | 31.84 |
|
| 1.29 | 7.27 | 54 | |
| immigrant | 1.03 | 0.92 | 0.58 | 1.81 | 1.32 | 0.48 | 0.61 | 2.83 | 1.17 | 0.49 | 0.75 | 1.84 | 503 | |
| visitor: born & live abroad | 0.70 | 0.45 | 0.28 | 1.96 | 1.78 | 0.73 | 0.19 | 3.26 | 0.78 | 0.53 | 0.36 | 1.69 | 226 | |
| Any STI test in last 12 months | no | ref. | 2249 | |||||||||||
| yes | 1.15 | 0.62 | 0.67 | 1.95 |
| 0.00 | 1.56 | 5.84 |
|
| 1.42 | 2.66 | 2007 | |
| STI diagnoses | no diagnosis | ref. | 3946 | |||||||||||
| 1 diagnosis | 0.71 | 0.36 | 0.34 | 1.48 |
|
| 2.10 | 18.05 | 1.24 | 0.43 | 0.72 | 2.14 | 310 | |
| 2 diagnoses | 1.03 | 0.97 | 0.31 | 3.35 | 4.96 | 0.14 | 0.60 | 41.01 | 1.40 | 0.52 | 0.50 | 3.88 | 74 | |
| 3 diagnoses | 1.07 | 0.95 | 0.14 | 8.10 | 1.00 | – | – | – | 1.44 | 0.73 | 0.19 | 10.88 | 18 | |
| 4 diagnoses | 1.00 | – | – | – | 1.00 | – | – | – | 1.00 | – | – | – | 8 | |
| 5 diagnoses | 6.04 | 0.12 | 0.62 | 58.66 | 1.00 | – | – | – | 8.15 | 0.07 | 0.84 | 78.82 | 4 | |
| any STI diagnosis | 0.82 | 0.52 | 0.46 | 1.49 |
|
| 2.23 | 16.06 | 1.31 | 0.26 | 0.82 | 2.09 | 414 | |
| Number of sex partners | no partner | ref. | 269 | |||||||||||
| 1 partner | 0.64 | 0.38 | 0.24 | 1.72 | 4.82 | 0.13 | 0.62 | 37.34 | 1.37 | 0.46 | 0.59 | 3.17 | 819 | |
| 2–3 partners | 0.78 | 0.59 | 0.31 | 1.96 | 3.73 | 0.21 | 0.47 | 29.34 | 1.34 | 0.48 | 0.59 | 3.07 | 981 | |
| 4–5 partners | 0.79 | 0.63 | 0.30 | 2.08 | 4.57 | 0.16 | 0.56 | 37.45 | 1.49 | 0.36 | 0.64 | 3.51 | 626 | |
| 6–10 partners | 0.67 | 0.43 | 0.25 | 1.80 |
|
| 1.08 | 64.42 | 1.62 | 0.26 | 0.70 | 3.73 | 701 | |
| > 10 partners | 0.99 | 0.89 | 0.40 | 2.47 |
|
| 1.30 | 79.90 |
|
| 1.01 | 5.14 | 748 | |
| Number of partners with condomless anal intercourse | no partner | ref. | 1499 | |||||||||||
| 1 partner | 0.57 | 0.06 | 0.32 | 1.02 | 1.30 | 0.54 | 0.57 | 2.96 | 0.85 | 0.49 | 0.55 | 1.33 | 1108 | |
| 2–3 partners | 1.13 | 0.65 | 0.67 | 1.90 |
|
| 0.95 | 4.68 | 1.36 | 0.16 | 0.89 | 2.07 | 839 | |
| 4–5 partners | 0.67 | 0.46 | 0.24 | 1.92 |
|
| 1.92 | 13.16 | 1.50 | 0.22 | 0.79 | 2.85 | 235 | |
| 6–10 partners | 1.17 | 0.75 | 0.45 | 3.05 | 2.94 | 0.10 | 0.80 | 10.67 | 1.79 | 0.09 | 0.92 | 3.50 | 182 | |
| > 10 partners |
|
| 1.14 | 6.30 |
|
| 3.75 | 43.93 |
|
| 1.83 | 6.88 | 106 | |
| Type of partners in last 6 months | steady partner(s) | ref. | 653 | |||||||||||
| non-steady partner(s) | 1.18 | 0.65 | 0.58 | 2.38 | 1.08 | 0.86 | 0.49 | 2.35 | 1.12 | 0.66 | 0.68 | 1.85 | 1297 | |
| s + ns partner(s) | 1.31 | 0.42 | 0.68 | 2.55 | 1.00 | 1.00 | 0.49 | 2.04 | 1.23 | 0.39 | 0.77 | 1.97 | 2001 | |
| no partner | 1.67 | 0.35 | 0.56 | 4.97 | 0.22 | 0.15 | 0.03 | 1.71 | 0.78 | 0.60 | 0.31 | 1.95 | 216 | |
| Anal sex in last 6 months | no anal sex | ref. | 857 | |||||||||||
| anal intercourse (with condom) | 0.87 | 0.65 | 0.47 | 1.59 | 1.21 | 0.67 | 0.50 | 2.95 | 1.12 | 0.65 | 0.69 | 1.84 | 1005 | |
| condomless anal intercourse | 0.80 | 0.43 | 0.47 | 1.38 |
|
| 0.99 | 3.85 | 1.30 | 0.21 | 0.86 | 1.98 | 2498 | |
| Type of partner at last anal sex | steady partner | ref. | 1880 | |||||||||||
| non-steady partner | 1.01 | 0.96 | 0.65 | 1.67 | 1.04 | 0.07 | 0.95 | 3.17 | 1.30 | 0.13 | 0.93 | 1.82 | 1760 | |
| more than one partner |
|
| 1.03 | 4.11 | 2.33 | 0.13 | 0.77 | 7.04 |
|
| 1.24 | 3.97 | 207 | |
| Sexual role with last AI partner | top | ref. | 1324 | |||||||||||
| bottom | 1.11 | 0.71 | 0.64 | 1.94 | 1.07 | 0.93 | 0.49 | 1.94 | 0.98 | 0.93 | 0.65 | 1.48 | 1265 | |
| versatile |
|
| 1.27 | 3.42 | 1.00 | 1.00 | 0.48 | 2.09 |
|
| 1.09 | 2.37 | 1035 | |
| Serostatus disclosure to last AI partner | no disclosure | ref. | 2400 | |||||||||||
| disclosure |
|
| 0.15 | 0.48 | 1.18 | 0.82 | 0.56 | 2.06 |
|
| 0.33 | 0.75 | 1262 | |
| Number of drugs consumed at last anal sex | 0 | ref. | 1959 | |||||||||||
| 1 |
|
| 1.37 | 3.91 | 0.91 | 0.75 | 0.50 | 1.66 |
|
| 1.04 | 2.16 | 1394 | |
| 2 |
|
| 1.58 | 5.61 | 0.99 | 0.99 | 0.41 | 2.42 |
|
| 1.08 | 2.79 | 516 | |
| 3 |
|
| 2.03 | 9.09 | 1.00 | – | – | – |
|
| 1.19 | 4.49 | 167 | |
| 4 |
|
| 1.79 | 11.80 | 2.04 | 0.50 | 0.26 | 15.97 |
|
| 1.46 | 7.55 | 76 | |
| 5 |
|
| 1.32 | 16.70 | 1.00 | – | – | – | 2.66 | 0.11 | 0.80 | 8.87 | 40 | |
| 6 |
|
| 1.89 | 54.64 | 7.66 | 0.07 | 0.83 | 70.60 |
|
| 2.25 | 29.82 | 15 | |
| 7 | 4.17 | 0.18 | 0.51 | 34.29 | 1.00 | – | – | – | 2.98 | 0.30 | 0.38 | 23.46 | 12 | |
| 8 | 1.00 | – | – | – | 1.00 | – | – | – | 1.00 | – | – | – | 6 | |
| 9 |
|
| 1.64 | 214.37 | 1.00 | – | – | – |
|
| 1.12 | 106.62 | 4 | |
| Type of drugs | no party drug | ref. | 3875 | |||||||||||
| party |
|
| 1.77 | 4.77 | 0.36 | 0.32 | 0.05 | 2.66 |
|
| 1.29 | 3.22 | 307 | |
| no chemsex drug | ref. | 4063 | ||||||||||||
| chemsex |
|
| 1.04 | 4.39 | 1.89 | 0.54 | 0.25 | 14.45 |
|
| 1.24 | 4.71 | 111 | |
| no sexual performance substance | ref. | 3326 | ||||||||||||
| sexual performance substance |
|
| 1.61 | 3.61 | 1.79 | 0.07 | 0.95 | 3.37 |
|
| 1.55 | 2.98 | 853 | |
| no cannabis | ref. | 3869 | ||||||||||||
| cannabis |
|
| 1.27 | 3.79 | 0.89 | 0.85 | 0.27 | 2.91 |
|
| 1.08 | 2.83 | 304 | |
| no alcohol | ref. | 2.324 | ||||||||||||
| alcohol |
|
| 1.26 | 2.84 | 0.70 | 0.23 | 0.40 | 1.25 | 1.33 | 0.07 | 0.98 | 1.80 | 1859 | |
| Satisfaction with sex life | unsatisfied | ref. | 950 | |||||||||||
| satisfied | 1.70 | 0.08 | 0.94 | 3.08 | 1.16 | 0.67 | 0.59 | 2.27 | 1.48 | 0.06 | 0.98 | 2.22 | 3.124 | |
Multivariate multilevel models to estimate associations between undiagnoseda HIV infection and demographic and behavioural parameters among participants of the Sialon II study
| Odds Ratio | [95% Conf. Interval] | ||||
|---|---|---|---|---|---|
| uHIVinc ( | |||||
| Age group | 18–24 | ref. | |||
| 25–34 |
|
| 1.03 | 4.99 | |
| 35–44 | 1.62 | 0.29 | 0.67 | 3.90 | |
| 45–54 | 1.37 | 0.56 | 0.48 | 3.96 | |
| 55+ | 1.08 | 0.91 | 0.26 | 4.46 | |
| Sexual role with last AI partner | top | ref. | |||
| bottom | 1.12 | 0.73 | 0.60 | 2.07 | |
| versatile |
|
| 1.18 | 3.55 | |
| Type of drugs during last anal sex | no use of ecstasy, cocaine, amphetamine | ref. | |||
| ecstasy, cocaine, amphetamine |
|
| 1.17 | 4.21 | |
| no use of sexual performance substances (poppers, erectile dysfunction medication) | ref. | ||||
| sexual performance substances (poppers, erectile dysfunction medication) |
|
| 1.17 | 3.28 | |
| Serostatus disclosure to last AI partner | disclosure | ref. | |||
| no disclosure |
|
| 2.14 | 7.27 | |
| _cons |
|
|
|
| |
| city |
|
|
|
| |
| uHIVunk ( | |||||
| Age group | 18–24 | ref. | |||
| 25–34 | 2.00 | 0.16 | 0.76 | 5.27 | |
| 35–44 |
|
| 1.41 | 9.84 | |
| 45–54 |
|
| 1.08 | 10.12 | |
| 55+ | 0.90 | 0.93 | 0.10 | 7.84 | |
| Number of partners with condomless anal intercourse | no partner | ref. | |||
| 1 partner | 1.46 | 0.38 | 0.63 | 3.36 | |
| 2–3 partners |
|
| 1.17 | 6.04 | |
| 4–5 partners |
|
| 2.26 | 16.40 | |
| 6–10 partners | 2.01 | 0.38 | 0.43 | 9.44 | |
| > 10 partners |
|
| 3.60 | 45.65 | |
| STI testing in last 12 months | no testing | ref. | |||
| any STI testing |
|
| 1.74 | 7.50 | |
| _cons |
|
|
|
| |
| city |
|
|
|
| |
| uHIV ( | |||||
| Age group | 18–24 | ref. | |||
| 25–34 |
|
| 1.33 | 4.19 | |
| 35–44 |
|
| 1.19 | 4.13 | |
| 45–54 | 1.90 | 0.09 | 0.91 | 3.94 | |
| 55+ | 0.85 | 0.78 | 0.27 | 2.66 | |
| HIV test in last 12 months and knowing the result | not tested | ref. | |||
| tested and knowing the result |
|
| 1.04 | 2.19 | |
| Number of partners with condomless anal intercourse | no partner | ref. | |||
| 1 partner | 0.85 | 0.50 | 0.54 | 1.35 | |
| 2–3 partners | 1.28 | 0.30 | 0.81 | 2.03 | |
| 4–5 partners | 1.35 | 0.39 | 0.68 | 2.69 | |
| 6–10 partners | 1.56 | 0.25 | 0.74 | 3.29 | |
| > 10 partners |
|
| 1.34 | 5.85 | |
| Type of drugs during last anal sex | no use of sexual performance substances (poppers, erectile dysfunction medication) | ref. | |||
| sexual performance substances (poppers, erectile dysfunction medication) |
|
| 1.32 | 2.76 | |
| _cons |
|
|
|
| |
| city |
|
|
|
| |
athe three models estimate associations in three groups:
uHIVinc – undiagnosed HIV in a group of men reporting a last negative HIV test result within the previous 12 months
uHIVunk – undiagnosed HIV in a group of men who never tested for HIV or whose last negative HIV test result is older than 12 months
uHIV – undiagnosed HIV in the combined group of men irrespective of the time of the last negative HIV test
| Country | City | Date of approval | Number of the doc | Name of the Ethics Committee |
|---|---|---|---|---|
| Belgium | Brussels | 18/3/2013 | ITG 860/13 | Ethics Committee – University of Antwerp |
| Bulgaria | Sofia | 26/3/2013 | – | Ethics Committee – National Centre of Infectious and Parasitic Diseases Sofia |
| Germany | Hamburg | 28/2/2013 | EA1/024/ 13 | Ethics Committee – Charité University |
| Italy | Verona | 22/05/2013 | Prot.N.25334; N.Prog. 2341 | Ethics Committee - Verona University Hospital |
| Lithuania | Vilnius | 14/05/2013 | N. 158,200–13–608-188 | Regional Ethics Committee Biomedical Research – Vilnius |
| Poland | Warsaw | 18/4/2013 | 1/2013 | Ethics Committee – Warsaw |
| Portugal | Lisbon | 14/6/2013 | 12–2013-PI | Ethics Committee - Instituto de Higiene e Medicina Tropical |
| Romania | Bucharest | 18/04/2013 | C. 1937 | Ethics Committee Institute M. Bals – Bucharest |
| Slovakia | Bratislava | 16/05/2013 | – | Ethics Committee of the Slovak Medical University |
| Slovenia | Ljubljana | 16/4/2013 | 87/04/13 | Ethics Committee Republic of Slovenia |
| Spain | Barcelona | 17/4/2013 | PI 13014 | Ethics Committee – Germans Trias i Pujol Hospital |
| Sweden | Stockholm | 14/5/2013 | 2013/3:5–2013–05-02 | Ethics Committee – Folkhalsomyndigheten |
| UK | Brighton | 26/01/2013 | FREGC-13-001.R1 | Faculty of Health and Social Science Research Ethics and Governance Committee |